NeoGenomics (NEO) Revenue & Revenue Breakdown
NeoGenomics Revenue Highlights
Latest Revenue (Y)
$591.64M
Latest Revenue (Q)
$164.50M
Main Segment (Y)
Clinical Services
NeoGenomics Revenue by Period
NeoGenomics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $591.64M | 16.07% |
| 2022-12-31 | $509.73M | 5.24% |
| 2021-12-31 | $484.33M | 8.97% |
| 2020-12-31 | $444.45M | 8.71% |
| 2019-12-31 | $408.83M | 47.73% |
| 2018-12-31 | $276.74M | 7.01% |
| 2017-12-31 | $258.61M | 5.95% |
| 2016-12-31 | $244.08M | 144.57% |
| 2015-12-31 | $99.80M | 14.62% |
| 2014-12-31 | $87.07M | 31.00% |
| 2013-12-31 | $66.47M | 11.02% |
| 2012-12-31 | $59.87M | 37.68% |
| 2011-12-31 | $43.48M | 26.51% |
| 2010-12-31 | $34.37M | 16.63% |
| 2009-12-31 | $29.47M | 47.23% |
| 2008-12-31 | $20.02M | 73.97% |
| 2007-12-31 | $11.50M | 77.65% |
| 2006-12-31 | $6.48M | 243.50% |
| 2005-12-31 | $1.89M | 237.83% |
| 2004-12-31 | $558.07K | 50.84% |
| 2003-12-31 | $369.97K | 295.73% |
| 2002-12-31 | $93.49K | 9249.10% |
| 2001-12-31 | $1.00K | -99.60% |
| 2000-12-31 | $252.40K | - |
NeoGenomics generated $591.64M in revenue during NA 2023, up 16.07% compared to the previous quarter, and up 213.79% compared to the same period a year ago.
NeoGenomics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $164.50M | 5.29% |
| 2024-03-31 | $156.24M | 0.44% |
| 2023-12-31 | $155.55M | 2.37% |
| 2023-09-30 | $151.95M | 3.43% |
| 2023-06-30 | $146.92M | 7.07% |
| 2023-03-31 | $137.22M | -1.07% |
| 2022-12-31 | $138.71M | 7.71% |
| 2022-09-30 | $128.78M | 2.97% |
| 2022-06-30 | $125.07M | 6.74% |
| 2022-03-31 | $117.17M | -6.81% |
| 2021-12-31 | $125.73M | 3.62% |
| 2021-09-30 | $121.34M | -0.32% |
| 2021-06-30 | $121.72M | 5.36% |
| 2021-03-31 | $115.53M | -8.30% |
| 2020-12-31 | $126.00M | 0.44% |
| 2020-09-30 | $125.44M | 44.23% |
| 2020-06-30 | $86.98M | -17.97% |
| 2020-03-31 | $106.03M | -0.78% |
| 2019-12-31 | $106.87M | 2.10% |
| 2019-09-30 | $104.67M | 2.91% |
| 2019-06-30 | $101.71M | 6.42% |
| 2019-03-31 | $95.58M | 24.98% |
| 2018-12-31 | $76.47M | 10.68% |
| 2018-09-30 | $69.10M | 1.99% |
| 2018-06-30 | $67.75M | 6.82% |
| 2018-03-31 | $63.42M | -6.44% |
| 2017-12-31 | $67.79M | 7.52% |
| 2017-09-30 | $63.05M | -4.60% |
| 2017-06-30 | $66.09M | 7.16% |
| 2017-03-31 | $61.68M | 1.96% |
| 2016-12-31 | $60.49M | -0.45% |
| 2016-09-30 | $60.76M | -3.75% |
| 2016-06-30 | $63.13M | 5.74% |
| 2016-03-31 | $59.70M | 118.86% |
| 2015-12-31 | $27.28M | 8.57% |
| 2015-09-30 | $25.13M | 3.10% |
| 2015-06-30 | $24.37M | 5.84% |
| 2015-03-31 | $23.03M | -7.89% |
| 2014-12-31 | $25.00M | 7.68% |
| 2014-09-30 | $23.22M | 12.32% |
| 2014-06-30 | $20.67M | 13.68% |
| 2014-03-31 | $18.18M | -0.77% |
| 2013-12-31 | $18.32M | 8.52% |
| 2013-09-30 | $16.88M | 8.21% |
| 2013-06-30 | $15.60M | -0.34% |
| 2013-03-31 | $15.66M | 5.12% |
| 2012-12-31 | $14.89M | 4.87% |
| 2012-09-30 | $14.20M | -9.03% |
| 2012-06-30 | $15.61M | 2.97% |
| 2012-03-31 | $15.16M | 17.58% |
| 2011-12-31 | $12.89M | 13.90% |
| 2011-09-30 | $11.32M | 8.16% |
| 2011-06-30 | $10.47M | 18.86% |
| 2011-03-31 | $8.80M | 0.57% |
| 2010-12-31 | $8.76M | 0.54% |
| 2010-09-30 | $8.71M | 2.57% |
| 2010-06-30 | $8.49M | 0.86% |
| 2010-03-31 | $8.42M | 7.93% |
| 2009-12-31 | $7.80M | 6.89% |
| 2009-09-30 | $7.30M | -2.18% |
| 2009-06-30 | $7.46M | 7.89% |
| 2009-03-31 | $6.91M | 16.78% |
| 2008-12-31 | $5.92M | 17.22% |
| 2008-09-30 | $5.05M | 3.47% |
| 2008-05-13 | $4.88M | 17.26% |
| 2008-03-31 | $4.16M | 9.68% |
| 2007-12-31 | $3.80M | - |
NeoGenomics generated $164.50M in revenue during Q2 2024, up 5.29% compared to the previous quarter, and up 119.88% compared to the same period a year ago.
NeoGenomics Revenue Breakdown
NeoGenomics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Clinical Services | $495.64M | $418.75M | $404.17M | $382.34M | $361.16M |
| Pharma Services | - | $90.97M | $80.16M | $62.11M | $47.67M |
NeoGenomics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Clinical Services (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Services | $141.39M | $134.53M | $130.06M | $127.55M | $123.16M | $114.87M | $108.17M | $106.16M | $105.64M | $98.79M | $104.05M | $102.23M | $101.41M | $96.49M | $106.74M | $108.73M | $73.88M | $92.98M | $93.40M | $92.56M |
| Pharma Services | - | $21.70M | $22.35M | $30.54M | $22.62M | $19.44M | $18.38M | $21.68M | $19.11M | $20.32M | $19.05M | $19.26M | $16.71M | $13.09M | $13.05M | $13.46M | $12.11M | - | - | - |
NeoGenomics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Clinical Services (100.00%).
NeoGenomics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IQV | IQVIA | $14.98B | $3.81B |
| ICLR | ICON Public | $8.12B | $2.09B |
| CRL | Charles River Laboratories | $4.13B | $1.03B |
| MTD | Mettler-Toledo | $3.79B | $946.75M |
| QGEN | Qiagen | $1.97B | $458.80M |
| NTRA | Natera | $1.08B | $413.35M |
| SHC | Sotera Health | $1.05B | $276.59M |
| NEOG | Neogen | $924.22M | $228.81M |
| MYGN | Myriad Genetics | $678.40M | $191.90M |
| NEO | NeoGenomics | $591.64M | $164.50M |
| GH | Guardant Health | $563.95M | $177.24M |
| CDNA | CareDx | $280.32M | $92.27M |
| TWST | Twist Bioscience | $245.11M | $81.46M |
| CSTL | Castle Biosciences | $219.79M | $87.00M |
| OLK | Olink AB (publ) | $169.91M | $28.59M |
| BDSX | Biodesix | $49.09M | $14.82M |
| ACRS | Aclaris Therapeutics | $31.25M | $2.40M |
NEO Revenue FAQ
What is NeoGenomics’s yearly revenue?
NeoGenomics's yearly revenue for 2023 was $591.64M, representing an increase of 16.07% compared to 2022. The company's yearly revenue for 2022 was $509.73M, representing an increase of 5.24% compared to 2021. NEO's yearly revenue for 2021 was $484.33M, representing an increase of 8.97% compared to 2020.
What is NeoGenomics’s quarterly revenue?
NeoGenomics's quarterly revenue for Q2 2024 was $164.5M, a 5.29% increase from the previous quarter (Q1 2024), and a 11.97% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $156.24M, a 0.44% increase from the previous quarter (Q4 2023), and a 13.86% increase year-over-year (Q1 2023). NEO's quarterly revenue for Q4 2023 was $155.55M, a 2.37% increase from the previous quarter (Q3 2023), and a 12.15% increase year-over-year (Q4 2022).
What is NeoGenomics’s revenue growth rate?
NeoGenomics's revenue growth rate for the last 3 years (2021-2023) was 22.16%, and for the last 5 years (2019-2023) was 44.72%.
What are NeoGenomics’s revenue streams?
NeoGenomics's revenue streams in c 23 are Clinical Services
What is NeoGenomics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of NeoGenomics was Clinical Services. This segment made a revenue of $495.64M, representing 100.00% of the company's total revenue.